Hacker News new | past | comments | ask | show | jobs | submit login

There's hope that this won't be an issue in the future:

https://www.reviewofoptometry.com/news/article/eye-drop-for-...

I've been following the development of this drug since before it was bought by Novartis.

I was expecting the average results to get better along with the median, but perhaps the dosage just wasn't high enough in this trial.




Very interesting! Hopefully they have more success in the future. Seems like an enormous market so hopefully there will be more investment.




Guidelines | FAQ | Lists | API | Security | Legal | Apply to YC | Contact

Search: